Preface – ESMO Lung Cancer 2022


© ElainePerks2013 – Charles Swanton, MBBS, PhD, FRCP, FMedSci, FRS, Francis Crick Institute and UCL Hospitals, London, United Kingdom

Dear Colleagues,

At the ESMO Congress held in Paris, France, and virtually from 9th to 13th September 2022, practice-changing data and high-quality education attracted more than 29,300 participants from over 150 countries. The 1,912 abstracts reported at the conference included 76 late-breaking abstracts, and 11 abstracts were selected for presidential symposia to discuss the most exciting updates across different tumor types including therapeutic innovations, translational research, patient advocacy, public policy, and many more.

This issue of memo inOncology summarizes some of the lung cancer highlights presented at the ESMO 2022 ­Congress. In the (neo)adjuvant setting, the data underscore the importance of patient selection and have confirmed innovative treatment approaches while demonstrating the potential of new combinations. An entire chapter is ­devoted to new ways to further improve patient outcomes in the setting of ­metastatic lung cancer by targeting KRASG12C, EGFR, HER2, and angiogenesis in the first and later lines. Among others, the results ­suggest a new second-line standard ­option for patients with advanced KRASG12C-mutated ­NSCLC and a po­tential chemotherapy-sparing targeted ­strategy in the treatment of patients with ­EGFR-mutant ­NSCLC harboring MET ­amplifications. Updates on immuno­therapy-based approaches show sustained outcome improvement with single agents or combination regimens. Immune checkpoint inhibition also offers an effective first-line alternative in the important understudied patient population with poor performance status who have mul­tiple comorbidities and poor tolerance of treatment.

Furthermore, data presented at ESMO dealt with the close association between air pollution and increased lung cancer risk, indicating a significant association between the exposure to atmospheric particulate matter with a diameter ≤ 2.5 μm and EGFR-mutant lung cancer incidence across the globe. Insights were also obtained with respect to the role of inflammation in the promotion of a cancer-stem-cell–like state. Last but not least, the benefits of lung cancer mass screening are discussed on the basis of a study conducted in China.

Once again, the ESMO meeting was a place to build strong, meaningful ­academic relationships with colleagues and peers in the field of lung cancer while concomitantly enabling an environment for sharing clinical cases and debates aiming at providing better care for patients.

© 2022 Springer-Verlag GmbH, Impressum

More posts